SXTC Closes $12M Direct Offering, Further Diluting Shareholders Amid Continued Cash Burn

What happened

China SXT Pharmaceuticals closed a $12 million registered direct offering through Univest Securities, adding to a series of dilutive capital raises. The company had already seen shares outstanding balloon from 13.8 million to 116 million in the six months through September 2025, and this new issuance further erodes per-share value. While the cash injection bolsters the balance sheet, core operations remain distressed: revenue fell 24% year-over-year in H1 FY26 to $0.63 million, with gross margin declining to 16.2%. Management has historically used such proceeds to fund operating losses and related-party loans rather than profitable growth, as evidenced by $0.9 million lent to related parties in H1 FY26. This offering therefore reinforces the bearish view that SXTC is a value-destroying vehicle for minority shareholders.

Implication

Investors should recognize that SXTC's cash balance is largely the product of relentless equity issuance, not operational success; the new $12 million only deepens the dilution. Without a credible plan to deploy capital into revenue-generating activities, the cash will likely be consumed by ongoing losses, as seen in the $6.4 million net loss in H1 FY26. The persistent pattern of low-priced offerings, combined with a shrinking TCMP business and VIE structural risks, suggests per-share value will continue to erode. Unless management demonstrates sustained revenue growth and margin improvement without further dilution, the stock remains a speculative bet with poor risk-reward. The smart move for most investors is to avoid SXTC entirely or treat it as a short candidate if tolerable.

Thesis delta

The core thesis remains a STRONG SELL: SXTC is a hyper-dilutive micro-cap with a deteriorating operating business. The new $12 million offering does not alter this view; it actually strengthens the bear case by further increasing share count and providing additional evidence that management relies on equity issuance rather than operational improvement. The only scenario for a positive shift would be a sustained turnaround in revenue and margins without further dilution, which appears unlikely.